You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed indolent lymphoma

Showing 51 - 75 of 9,273
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-Hodgkin Lymphoma Trial in Taiwan, United States (CHO-H01)

Recruiting
  • Non-Hodgkin Lymphoma
  • CHO-H01
  • The Woodlands, Texas
  • +7 more
Jul 10, 2023

Lymphoma Trial in Houston (Ibritumomab Tiuxetan (Zevalin), Rituximab)

Completed
Has Results
  • Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 30, 2022

Lymphoma, Non-Hodgkin Trial in Mainz (Obinutuzumab and Pixantrone)

Completed
  • Lymphoma, Non-Hodgkin
  • Obinutuzumab and Pixantrone
  • Mainz, RLP, Germany
    Department of Hematology, Oncology and Pneumology; University Me
Mar 30, 2022

Follicular Lymphoma, Mantle Cell Lymphoma Trial in New York (Ribavirin)

Terminated
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • New York, New York
    Weill Cornell Medicine
Sep 20, 2021

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Spokane, Salamanca (Zilovertamab vedotin,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Spokane, Washington
  • +1 more
Aug 12, 2022

Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • infusion of JY231 injection
  • Guangzhou, Guangdong, China
    Guangdong Second Provincial General Hospital
Sep 17, 2023

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

Non Hodgkin Lymphoma Trial in Australia, United Kingdom, United States (Magrolimab, Rituximab, Gemcitabine)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Birmingham, Alabama
  • +19 more
Dec 8, 2022

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)

Recruiting
  • Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 20, 2022

Hematopoietic Cell Transplantation Recipient, Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma Trial in Columbus

Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • +11 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 29, 2021

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)

Recruiting
  • Lymphoma
  • +3 more
  • obinutuzumab
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

Not yet recruiting
  • Mantle-cell Lymphoma
  • Polatuzumab, bendamustin und rituximab
  • (no location specified)
May 11, 2023

Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Relmacabtagene Autoleucel Injection
  • (no location specified)
Apr 13, 2023

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Duarte, California
  • +1 more
Oct 13, 2023

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Refractory, Non-Hodgkin's Lymphoma, Relapsed

Recruiting
  • Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Autologous CAR19 T lymphocytes
  • Prague, Czechia
    Institute of Hematology and Blood Transfusion, Czech Republic
Aug 3, 2022

Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Trial in United States (TAK-007, Chemotherapy Agents)

Recruiting
  • Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
  • TAK-007
  • Chemotherapy Agents
  • Birmingham, Alabama
  • +18 more
Aug 17, 2022

Refractory Indolent Adult Non-Hodgkin Lymphoma Trial in Shijiazhuang (CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T)

Recruiting
  • Refractory Indolent Adult Non-Hodgkin Lymphoma
  • CD19 CAR-T
  • +4 more
  • Shijiazhuang, Hebei, China
    No.2 Hospital of Hebei Medical University
Nov 11, 2020

Severe COVID-19 Infection in CLL or B-NHL Who Received

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
    • (no location specified)
    Apr 6, 2023

    Non-hodgkin's Lymphoma Trial in Beijing (GNC-035)

    Not yet recruiting
    • Non-hodgkin's Lymphoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Sep 27, 2023